Although UI is an extremely common problem, and has a significant impact on quality of life, the vast majority of those who experience the condition do not undergo treatment, in part due to cost, embarrassment, or fear of risky surgical procedures. There is therefore a very strong demand for less costly, less invasive and more tolerable, discreet, nonsurgical UI therapies.
While current economic conditions and other factors continue to restrain market growth, the market for minimally invasive UI therapy systems is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $190 million in 2010, the U.S. Minimally Invasive Urinary Incontinence Therapy Systems market is expected to increase at a healthy compound annual rate of 2.7%, with sales reaching more than $220 million in 2015. The market is expected to benefit not only from strong demand but from highly positive demographic trends, including a large, growing UI population and limited options for truly effective therapeutic alternatives.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include injectable urethral bulking agents; urethral sling systems; implantable sacral nerve neurostimulators; nonsurgical office-based neuromodulation/percutaneous tibial nerve stimulation; and other nonsurgical treatments.
EXECUTIVE SUMMARY ii. Stress Urinary Incontinence iii. Overactive Bladder and Urge Incontinence iv. Treatment a. Prescription Drug Therapy b. Botulinum Toxin c. Bulking Agents d. Implantable Neurostimulation e. Percutaneous Tibial Nerve Stimulation f. Urethral Slings g. Surgical Options v. Minimally Invasive Urinary Incontinence Therapy Systems Market a. Procedure Volumes b. Market Forecast vi. Methodology Exhibit ES-1: Minimally Invasive Urinary Incontinence Therapy, Procedure Volumes Forecast, 2010-2015 Exhibit ES-2: Minimally Invasive Urinary Incontinence Therapy Systems, Market Forecast, 2010-2015 1. CLINICAL OVERVIEW OF URINARY INCONTINENCE 1.1 Anatomy of the Urinary System 1.2 Types of Urinary Incontinence 1.2.1 Stress Urinary Incontinence 220.127.116.11 Causes 1.2.2 Overactive Bladder and Urge Incontinence 18.104.22.168 Causes 1.3 Treatment 1.3.1 Prescription Drug Therapy 1.3.2 Botulinum Toxin 1.3.3 Bulking Agents 1.3.4 Sacral Nerve Stimulation 22.214.171.124 Implantable Neurostimulation 126.96.36.199 Percutaneous Tibial Nerve Stimulation 1.3.5 Urethral Slings 1.3.6 Surgical Options Exhibit 1-1: Urinary Voiding and Afferent Signaling Exhibit 1-2: Sacral Neuromodulation with an Implanted Electrical Stimulator 2. MINIMALLY INVASIVE URETHRAL BULKING AGENTS 2.1 Selected Products 2.1.1 Contigen 2.1.2 Coaptite 2.1.3 Durasphere EXP 2.1.4 Macroplastique 2.1.5 Bulkamid 2.2 Market Analysis 2.2.1 Procedure Volumes 2.2.2 Market Forecast 2.2.3 Competitive Analysis Exhibit 2-1: The Coaptite Injectable Implant Procedure Exhibit 2-2: The Macroplastique Urethral Bulking Agent Exhibit 2-3: Macroplastique Treatment, Key Efficacy Results at 12 Months Exhibit 2-4: Macroplastique Treatment, Key Adverse Events Exhibit 2-5: Minimally Invasive Urethral Bulking Agent Therapy, Procedure Volumes Forecast, 2010-2015 Exhibit 2-6: Minimally Invasive Urethral Bulking Agents, Market Forecast, 2010-2015 Exhibit 2-7: 2010, Minimally Invasive Urethral Bulking Agents Market, Share by Supplier 3. MINIMALLY INVASIVE URETHRAL SLING SYSTEMS 3.1 Selected Products 3.1.1 American Medical Systems/Endo Pharmaceuticals 188.8.131.52 Urethral Slings for Women 184.108.40.206 Urethral Slings for Men 3.1.2 Bard Medical/C.R. Bard 3.1.3 Boston Scientific 3.1.4 Caldera Medical 3.1.5 Coloplast 3.1.6 Cook Medical/Cook Group 3.1.7 Ethicon/Johnson & Johnson 3.1.8 Promedon 3.2 Market Analysis 3.2.1 Procedure Volumes 3.2.2 Market Forecast 3.2.3 Competitive Analysis Exhibit 3-1: 2011, Selected Urethral Sling Systems Exhibit 3-2: The MiniArc Precise Single-Incision Sling System Exhibit 3-3: The MiniArc Single-Incision Sling Exhibit 3-4: The Monarc Subfascial Hammock Exhibit 3-5: Suprapubic and Transobturator Approaches to Mid-Urethral Sling Placement Using the BioArc SP and BioArc TO Sling Systems Exhibit 3-6: 12-Step Mid-Urethral Sling Implant Procedure Using the BioArc SP Sling System Exhibit 3-7: The In-Fast Ultra Transvaginal Sling Exhibit 3-8: The Ajust Adjustable Single-Incision Sling Exhibit 3-9: The Align Urethral Support System Exhibit 3-10: The PelviLace Biourethral Support System Exhibit 3-11: The Advantage Fit System Exhibit 3-12: Components of the Advantage Transvaginal Mid-Urethral Sling System Exhibit 3-13: Steps in a Mid-Urethral Sling Implant Procedure Using the Advantage Sling System Exhibit 3-14: The Desara Sling System Exhibit 3-15: Mesh Integrity, Comparison of the Desara Mesh with Other Slings Exhibit 3-16: The Aris Transobturator Sling System Exhibit 3-17: The Biodesign Tension-Free Urethral Sling Exhibit 3-18: The TVT ABBREVO Continence System Exhibit 3-19: Safety Advantages of the TVT ABBREVO Procedure Exhibit 3-20: Comparable Clinical Improvement at 12 months, Modified TVT Obturator System versus the Unaltered TVT Obturator System Exhibit 3-21: TVT Tension-Free Support for Incontinence and TVT EXACT Continence Systems, Comparative Perforation and Voiding Dysfunction Rates Exhibit 3-22: Comparative Benefits of the TVT SECUR Mini Single-Incision Sling as Compared with the MiniArc Sling System Exhibit 3-23: The Ophira Mini Sling System Exhibit 3-24: The Argus Adjustable Male Sling System Exhibit 3-25: Minimally Invasive Urethral Sling Implantation, Procedure Volumes Forecast, 2010-2015 Exhibit 3-26: Minimally Invasive Urethral Sling Systems, Market Forecast, 2010-2015 Exhibit 3-27: 2010, Minimally Invasive Urethral Sling Systems Market, Share by Supplier 4. SACRAL NERVE STIMULATION 4.1 Selected Products 4.1.1 InterStim Therapy System 4.1.2 Urgent PC Neuromodulation System 4.2 Market Analysis Exhibit 4-1: The InterStim Therapy System Exhibit 4-2: InterStim Therapy, 12-Month and 5-Year Sustained Clinical Efficacy Exhibit 4-3: The Sacral Plexus Exhibit 4-4: The Urgent PC Neuromodulation System Exhibit 4-5: Summary of a Meta-Analysis of Percutaneous Tibial Nerve Stimulation Using the Urgent PC Neuromodulation System 5. NONSURGICAL INCONTINENCE THERAPIES 5.1 Selected Products 5.1.1 Renessa System 5.1.2 NeoControl Pelvic Floor Therapy System 5.1.3 MS-106 Twin and MS-310 Pelvic Floor Stimulators 5.1.4 Liberty System Exhibit 5-1: The Renessa System and Benefits of Treatment Exhibit 5-2: Renessa Therapy's Place in the Spectrum of Treatment Options Exhibit 5-3: The Renessa Procedure and Mechanism of Action Exhibit 5-4: NeoControl Pelvic Floor Therapy and Mechanism of Action Exhibit 5-5: The MS-106 Twin and MS-310 Pelvic Floor Stimulators Exhibit 5-6: Liberty System Pelvic Floor Stimulator 6. COMPANY PROFILES 6.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc. 6.2 C.R. Bard, Inc. 6.3 Boston Scientific Corporation 6.4 Caldera Medical, Inc. 6.5 Coloplast AS 6.6 Contura International AS/Idosan AS 6.7 Cook Group, Inc. 6.8 Johnson & Johnson 6.9 Medtronic, Inc. 6.10 Uroplasty, Inc. APPENDIX: COMPANY LISTING